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Objectives: Nonbiodegradable synthetic materials have been widely used to repair
cardiac defects. Material-related failures, however, such as lack of growth, throm-
bosis, and infection, do occur. Because a biodegradable scaffold can be replaced by
the patient’s own cells and will be treated as a foreign body for a limited period, we
compared four biodegradable materials (gelatin, polyglycolic acid (PGA), and
copolymer made of -caprolactone and L-lactic acid reinforced with a poly-L-lactide
knitted [KN-PCLA] or woven fabric [WV-PCLA]) with a nonbiodegradable poly-
tetrafluoroethylene (PTFE) material. An animal heart model was tested that simu-
lates the in vivo clinical condition to which a synthetic material would be used.
Methods: The five patches were used to repair transmural defects surgically created
in the right ventricular outflow tracts of adult rat hearts (n  5, each patch group).
The PTFE patch group served as a control group. At 8 weeks after implantation, the
biomaterials were excised. Patch size, patch thickness, infiltrated cell number,
extracellular matrix composition, and patch degradation were evaluated.
Results: The PTFE patch itself did not change in size except for increasing in
thickness because of fibroblast and collagen coverage of both its surfaces. Host cells
did not migrate into the PTFE biomaterial. In contrast, cells migrated into the
biodegrading gelatin, PGA, and KN-PCLA and WV-PCLA scaffolds. Cellular ingrowth
per unit patch area was highest in the KN-PCLA patch. The KN-PCLA patch increased
modestly in size and thinness. The WV-PCNA patch did not change in size or thickness.
Fibroblasts and collagen were the dominant cellular infiltrate and extracellular matrix
formed in the biodegrading scaffolds. The in vivo rates of biomaterial degradation,
thinning, and expansion were material specific. All the subendocardial patch surfaces
were covered with endothelial cells. No thrombi were seen.
Conclusions: The unique, spongy matrix structure of the PCLA patch favored cell
colonization relative to the other patches. The strong, durable outer poly-L-lactide
fabric layers in these patches offered physical, biocompatible, and bioresorbable
advantages relative to the other biodegradable materials studied. Host cells migrated
into all the biomaterials. The cells secreted matrix and formed tissue, which was
endothelialized on the endocardial surface. The biomaterial degradation rates and
the tissue formation rates were material related. The PCLA grafts hold promise to
become a suitable patch for surgical repair.
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Aconduit from the right ventricle to thepulmonary artery has made possible thecorrection of numerous complex congen-ital cardiac anomalies that previouslywere uncorrectable.1 A transannular patchis also mandatory for children with tetral-
ogy of Fallot, double-outlet right ventricle with pulmonary
stenosis, or the similar anomalies in the right ventricular
outflow tract (RVOT). Currently, the conduits or patches are
made of Dacron polyester fabric, polytetrafluoroethylene
(PTFE), glutaraldehyde-treated bovine pericardium, or an-
tibiotic-preserved or cryopreserved homografts.2 The long-
term results have been compromised by material-related
failures.3 The materials are not viable, do not grow, and do
not provide pulsatile flow. Lack of growth of the surgical
biomaterial can necessitate reoperations to replace the patch
or conduit because of the child’s growth.4 Synthetic mate-
rial is treated by the patient’s immune system as a foreign
body and may become thrombogenic and infected.
Since the biodegradable scaffold needs to be capable of
resisting damage from the contracting myocardium and be
bioresorbable at a rate compatible with the repair process,
we studied the in vivo characteristics of acellular scaffolds
used to repair a surgically created myocardial defect in the
right ventricle of the adult rat. Nonbiodegradable PTFE and
biodegradable gelatin sponge, biodegradable nonwoven
polyglycolic acid (PGA) mesh, and biodegradable poly-L-
lactide knitted or woven fabric with a 50% -caprolactone
and 50% L-lactide spongy copolymer (PCLA) were tested.
At 8 weeks after surgical repair we found that material
degradation, expansion, host cell migration, and tissue for-
mation were material related. All the patches were endothe-
lialized on the endocardial surface. Our results indicated
that PCLA patches may be the most suitable of the biode-
gradable biomaterial that we studied for future myocardial
cellular engineering.
Methods
Experimental Animals
All animal procedures were carried out in compliance with the
“Guide to the Care and Use of Experimental Animals” of the
Canadian Council on Animal Care and the “Guide for the Care and
Use of Laboratory Animals” prepared by the Institute of Labora-
tory Animal Resources, National Research Council, and published
by the National Academy Press, revised 1996. Male syngeneic
Lewis rats (Charles River Canada Inc, Quebec, Quebec, Canada)
weighing 300 to 350 g were used for the RVOT replacement
procedure.
Biomaterial
Five materials were used in the in vivo studies: sheets of expanded
PTFE,* gelatin sponge (Gelfoam; Pharmacia Co, Kalamazoo,
Mich), PGA (Medifit; JMS Inc, Hiroshima, Japan), and biodegrad-
able poly-L-lactide knitted (KN) or woven (WV) fabric with PCLA
(Gunze Ltd, Kyoto, Japan). Rectangular pieces (7  7  0.4 mm
for PTFE, 7  7  3 mm for gelatin, 7  7  0.5 mm for PGA,
7  7  1 mm for KN-PCLA, 7  7  0.5 mm for WV-PCLA)
were used for the right ventricular wall replacement.
Right Ventricular Outflow Tract Free Wall Resection
and Replacement With Patches
The rats were anesthetized with an intramuscular injection of
ketamine hydrochloride (22 mg/kg), followed by an intraperitoneal
injection of sodium pentobarbital (30 mg/kg). The rats were intu-
bated and ventilated at a rate of 60 cycles/min with a tidal volume
of 3 mL under room air supplemented with oxygen (2 L/min) and
1% to 2.5% isoflurane.
The rat heart was exposed through a median sternotomy. A
purse-string suture (5-6 mm in diameter) was placed in the free
wall of the RVOT. Both ends of the suture were passed through a
22-gauge plastic vascular cannula (Angiocath; Becton Dickinson
and Company, Franklin Lakes, NJ), which was used as a tourni-
quet. The tourniquet was tightened, and the bulging part of the
RVOT wall inside the purse-string stitch was lopped off. The
tourniquet was briefly loosened to assess whether massive bleed-
ing occurred, indicating that a significant defect had been created
in the RVOT.5 A patch of nonbiodegradable PTFE or biodegrad-
able gelatin, PGA, KN-PCLA, or WV-PCLA (n  5 per group)
was sutured along the margin of the purse-string suture with an
over-and-over method with 7-0 polypropylene (Prolene; Ethicon,
Inc, Somerville, NJ) to cover the defect in the RVOT. The tour-
niquet was released and the purse-string suture was removed. The
chest incision was closed in layers with running sutures of 3-0 silk.
Penicillin G benzathine at 150,000 U/mL and penicillin G
procaine at 150,000 U/mL (Penlong XL) was injected intramus-
cularly (0.4 mL per rat). Buprenorphine hydrochloride (0.01 mg/
kg) was given subcutaneously every 8 hours for the first 48 hours
after the operation. After the operation, rats were monitored in a
warm environment until they had completely recovered from the
anesthesia and were then returned to their cages.
Morphologic Evaluations of the Patches in Vivo
Immediately after trimming of the patch to repair the defect in the
RVOT, the preoperative patch area was measured with a scale and
a digital video camera (DCR-PC110; Sony Corporation, Tokyo,
Japan). Eight weeks later the animals were killed with an intra-
peritoneal injection of 0.2 mL of pentobarbital sodium (Euthanyl;
MTC Pharmaceuticals, Cambridge, Ontario, Canada) after intra-
muscular injection of 200 units of heparin. Each heart was excised
through a median sternotomy and fixed with 10% phosphate-
buffered formalin solution for 2 days. The patch area of the RVOT
was remeasured with a scale by using the digital video camera. The
ratios of preoperative and postoperative patch areas were calcu-
lated and compared among all groups.
The right ventricular free wall was then cut in half through the
center of the patch. The thickness of the center of the patch
replacing the defect in the RVOT was measured. The ratios of the
preoperative and postoperative patch thicknesses were calculated
and compared among groups.
*Gore-Tex, registered trademark of W. L. Gore & Associates, Inc, Flagstaff,
Ariz.
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Histologic Studies of the Patches in Vivo
The 8-week-old implanted patches were processed with JFC solu-
tion (Milestone Srl, Sorisole, Italy), embedded in paraffin, and
sectioned to yield 3-m thick specimens. The sections were
stained with hematoxylin and eosin as described in the manufac-
ture’s specifications (Sigma Diagnostics, St Louis, Mo), with Mas-
son trichrome to assess the extracellular matrix,6,7 with a mono-
clonal antibody against vimentin (1:2000, monoclonal V9; Sigma)
to assess fibroblast growth, and with an antibody against factor
VIII (Polyclonal 1:2000; DAKO Corporation, Carpinteria, Calif)
to identify endothelial cells.
Histologic Analysis of the Implanted Patches
Five different 400-power microscopic fields (ECLIPSE-TE200;
Nikon Corporation, Tokyo, Japan) of each section of the RVOT
were randomly selected and photographed with a digital camera
(Coolpix; Nikon). All the digital images of morphologic and
histologic characteristics of the patch portion of the RVOT were
analyzed with the National Institutes of Health Image program
(version 1.62; National Institutes of Health, Springfield, Va).
Briefly, after tracing of the outline of the target areas in the section
and subtraction of the backgrounds, the color images were con-
verted to corresponding gray images. A fixed threshold (90 in 255
grades) of gray color scale determined automatically the number of
nuclei staining positively for hematoxylin.
Protein Assay of Scaffolds
The protein content in the remaining half of the patch was ex-
tracted. After being washed with buffer, the patch was homoge-
nized with protein extraction solution (50-mmol/L tris[hydroxym-
ethyl aminomethane hydrochloride, 0.5-g/mL aprotinin, 0.5-
g/mL pepstatin A, and 0.5-g/mL leupeptin) and centrifuged at
4°C at 14,000 rpm for 15 minutes. The supernatant was collected.
Serial bovine serum albumin solutions were prepared for the
standard protein solution as follows: 2, 1, 0.5, 0.25, 0.125, and
0.0625 mg/mL with 50-mmol/L tris(hydroxymethyl)aminometh-
ane hydrochloride (pH 7.4). The 495 L of protein assay solution
(BIO-RAD Dye and 0.9% sodium chloride at 5:1; Bio-Rad Lab-
oratories Inc, Hercules, Calif) and 5 L of each protein standard or
sample solution were mixed and read with a spectrophotometer
(model DU 640; Beckman Coulter, Inc, Fullerton, Calif) at a
wavelength of 595 nm. A standard curve was constructed to
measure protein concentrations. Gelatin patches were excluded in
the assay, because gelatin is also measured by the protein assay.
All other patch materials had no measurable protein content. The
patch protein content per cubic millimeter was obtained by divid-
ing the protein content by the patch cubic volume.
Data Analysis
All data are expressed as mean SE. StatView statistical software
(SAS Institute Inc, Cary, NC) was used to analyze statistical data.
The changes between the preoperative and postoperative patch
areas and thicknesses in each group were compared by a paired t
test. Comparisons among the five groups were performed by 1-way
analysis of variance. The Scheffe´ test was used to specify differ-
ences among groups when the F ratio of the analysis of variance
was significant.
Results
Biomaterial Area and Thickness Changes in Vivo
There were no significant differences in preoperative patch
area among the five biomaterials (PTFE 16.6  1.5 mm2,
gelatin 16.8  1.5 mm2, PGA 17.3  1.2 mm2, KN-PCLA
16.9  1.0 mm2, WV-PCLA 17.3  2.1 mm2, n  5 for
each group).
Patch area. Eight weeks after implantation, the changes
in the patch area (the ratios of postoperative to preoperative
values) were different among the five materials (Figure 1,
A). The nonbiodegradable PTFE patch did not change in
Figure 1. Percentage changes of patch area (A) and thickness (B)
after 8 weeks of implantation into defect in RVOT of adult rats.
Nonbiodegradable PTFE graft and four biodegradable grafts (gel-
atin [GEL], PGA, KN-PCLA, and WV-PCLA) were tested. Only PTFE
and WV-PCLA grafts did not change in area. Other grafts in-
creased in area. Although PTFE patch itself did not change, its
thickness increased 165.3% because of fibroblast growth and
collagen deposition on both sides of patch. Gelatin patch thinned
to 13% of its preoperative thickness and was thinner (P < .01,
P < .01, P < .01, and P < .01, respectively) than PTFE, PGA,
KN-PCLA, and WV-PCLA patches. In the PGA and KN-PCLA
patches but not in the WV-PCLA patch, thickness decreased (P <
.05) during 8 weeks in RVOT. a, P < .01 compared with GEL and
PCA; b, P < .05 compared with GEL; c, P < .01 compared with
PGA and PCLA; d, P < .05 PGA compared with WV-PCLA.
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area. However, the biodegradable gelatin and PGA patches
expanded significantly (P  .01 for both) relative to the
PTFE patch area. The KN-PCLA patch was larger (P .05)
than the PTFE patch but significantly smaller (P .05) than
the gelatin patch. The KN-PCLA and PGA patch areas did
not differ. The WV-PCLA patch did not expend in area and
was not statistically different in size from that of the KN-
PCLA patch. The KN-PCLA patch size was smaller in area
than the gelatin and PGA patches (P  .01 for both).
Patch thickness. The thickness of the biomaterials
changed during the 8 weeks of implantation (Figure 1, B).
Although the PTFE patch itself did not change, its thickness
increased 165.3% because of fibroblast growth and collagen
deposition on both sides of the patch. The gelatin patch
thinned to 13% of its preoperative thickness and was thinner
(P  .01 in all cases) than the PTFE, PGA, KN-PCLA, and
WV-PCLA patches. The PGA and KN-PCLA patches, but
not the WV-PCLA patch, decreased in thickness (P  .05,
P  .05) during the 8 weeks in the RVOT.
Cell Migration and Extracellular Matrix Formation in
the Biomaterials
Only the surfaces of the PTFE patch were coated with
fibroblasts (Figure 2, A) and collagen (Figure 3, A). No
cellular infiltration was evident within the PTFE patch. The
PTFE patch remained unchanged. In contrast, fibroblast
ingrowth (Figure 2, B-E) and collagen formation (Figure 3,
B-E) were present throughout the gelatin, PGA, KN-PCLA,
and WV-PCLA patches. Of the biodegradable materials, the
highest cell number per unit area was measured in the
KN-PCLA patch (Figure 4). No significant differences in
cell numbers were found among the gelatin, PGA, and
WV-PCLA patches. Two of five gelatin patches had foci of
inflammatory cells. The gelatin, PGA, KN-PCLA, and WV-
PCLA materials were partially absorbed and replaced by
fibroblasts and collagen (Figure 2, B- E, and Figure 3, B-E).
At 8 weeks after patch implantation, the patch protein
levels (measurement of both the cellular and matrix protein
levels) of 7.8 1.4 g/mm3 in the KN-PCLA patches (n 5)
and 7.4 1.6 g/mm3 in the WV-PCLA patches (n 4) were
greater (P  .01 and P  .05, respectively) than the protein
levels of 1.8 0.5 g/mm3 in the PGA patch (n 5) and 1.0
 0.3 g/mm3 in the PTFE patch (n 4). Because the gelatin
patch was itself proteinaceous, its protein levels were not
measured.
Endothelialization
At 8 weeks after implantation all the patches were endothe-
lialized on their endocardial surfaces (Figure 5). No thrombi
were observed on the patches.
Figure 2. Host cell growth in patch scaffolds at 8 weeks after implantation into defect in RVOT of adult rats (original
magnification 200). Patches were stained for fibroblasts with monoclonal antibody against vimentin. Patches
studied were PTFE (A), gelatin (B), PGA (C), KN-PCLA (D), and WV-PCLA (E). Host fibroblasts (brownish cells) grew
onto surface of PTFE scaffold (yellow arrow) and grew into gelatin, PGA, KN-PCLA, and WV-PCLA scaffolds (yellow
arrows).
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Discussion
Current bioprosthetic replacement devices expose the pa-
tient to the risks of thrombosis, the problem of limited
durability, and frequently the requirement for reoperation
because of the lack of patch growth.8 The important role for
the scaffolds in building biocompatible and viable prosthe-
ses to repair heart defects is to facilitate host cell attachment
and proliferation and to enhance the formation of the extra-
cellular matrix. It is well known in cell culture studies that
unless cultured cells can attach to the scaffolding, they will
die.9 Cellular growth is required in the scaffold to form
tissue and extracellular matrix. Seeding different cell types
in vitro can affect the composition of the extracellular
matrix. Smooth muscle cells will form collagen and elastin,
whereas fibroblasts will usually synthesize only collagen.
A biodegradable scaffold should be preferable to a non-
biodegradable scaffold. A biodegradable scaffold can be
replaced by the patient’s own cells and will be treated as a
foreign body for only a limited time. The PTFE patch has
been accepted worldwide as one of the most reliable non-
biodegradable synthetic materials10 in terms of durability,
low thrombogenicity, and comfortable handling for surgery.
Unfortunately, it does not grow as a child’s heart or blood
vessel grows, and it carries increased susceptibility to in-
fection.11 In this study PTFE was used as a control patch for
comparison purposes with the biodegradable patches that
we studied. The biodegradable gelatin sponge (Gelfoam)
was tested because of our earlier works.5,12,13 The use of
fetal cardiomyocytes the pliable and fragile gelatin scaffold
enabled us to create in vitro and in vivo beating patches. The
biodegradable nonwoven PGA mesh was studied because it
is one of the most common and attractive synthetic biode-
gradable polymers for tissue engineering field.14 However,
this PGA has recently been used in combination with an-
Figure 3. Extracellular matrix in patch scaffolds at 8 weeks after implantation into defect in RVOT of adult rats
(original magnification 200). Patches studied were PTFE (A), gelatin (B), PGA (C), KN-PCLA (D), and WV-PCLA (E).
Collagen in patches was stained with Masson trichrome. Collagen (light green in color, red arrows) was found in
all biomaterials, as indicated by yellow arrows.
Figure 4. Numbers of host cells in patch scaffolds at 8 weeks after
implantation into defect in RVOT of adult rats. Patches studied
(n  5 for each biomaterial) were PTFE, gelatin (GEL), PGA,
KN-PCLA, and WV-PCLA. KN-PCLA patch contained largest num-
ber of cells. PTFE patch contained no cells. Asterisk indicates
P < .01; dagger indicates P < .001 versus other groups.
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other biodegradable polymer,7,15,16 because nonwoven
meshes of PGA fibers lack structural stability and often
cannot maintain their original structure during tissue devel-
opment.17 Of special interest to us was the PCLA patch with
a biodegradable spongy matrix, reinforced on the outside
with a knitted or woven poly-L-lactide fabric that takes
between 1 and 2 years to biodegrade (information provided
by the manufacturer). We thought that the spongy matrix
would favor in vitro and in vivo cell growth and might be
suitable for in vitro autologous seeding of smooth muscle
cells or stem cell–derived cardiomyocytes. Also, the outer
fabric of PCLA patch should provide structural stability and
permit sufficient time for in vivo maturation of the seeded
cells in the contracting ventricular wall. Kim and Mooney17
demonstrated that the poly-L-lactide–bonded PGA matrices
had a high cellularity and maintained their predefined struc-
ture more than did the unbonded PGA matrices during the
process of tissue development in vitro. Their report suggests
that the combined scaffold structure, like the PCLA patch in
our study, should allow the maintenance of the configura-
tion and dimension of the original matrices and the devel-
opment of a new tissue in a predefined 3-dimensional struc-
ture.
Because Carver,18 Freed,19 and their colleagues have
shown that mechanical stimuli and pressure can enhance
cellular formation of extracellular matrix and tissue regen-
eration, we used an animal model that simulates the in vivo
conditions to which a tissue patch would be exposed clini-
cally. In addition to the mechanical forces of myocardial
contractility, the patch is influenced by the myocardial tis-
sue milieu and is in direct contact with the blood in the right
ventricular chamber. An 8-week period of in vivo testing
was arbitrarily chosen as being sufficiently long to detect
graft failure and to compare the various scaffolds.
The PTFE scaffold did not change in its dimensions or
break down after 8 weeks as a patch in the RVOT. Com-
pared with the biodegradable patches, PTFE permitted only
surface cell growth that consisted predominantly of fibro-
blasts. Fibrous tissue was firmly attached onto both surfaces
of the patch. No inflammatory infiltration was noted. The
gelatin patch was unsuitable as a patch because of its
marked expansion and thinning. The gelatin scaffold was
almost completely degraded and infiltrated with fibroblasts.
Additionally, some inflammatory foci were found. Because
this phenomenon was found in one of our earlier studies,5
we believe that the inflammatory reaction was caused by a
xenogenic reaction to porcine skin proteins in the sponge.
The nonwoven PGA patch increased in surface area and
thinned after 8 weeks in the RVOT. The scaffold itself was
almost completely degraded and infiltrated with fibroblasts.
The expansion of the patch size during the 8 weeks indi-
cated either that the scaffold biodegradation process was not
Figure 5. Endothelialization of patch scaffolds at 8 weeks after implantation into defect in RVOT of adult rats
(original magnification 200). Endothelial cells were identified by immunohistochemical staining for factor VIII.
Patches studied were PTFE (A), gelatin, (B), PGA (C), KN-PCLA (D), and WV-PCLA (E). Endothelial cells (brownish
cells, red arrows) covered endocardial surfaces of all biomaterial scaffolds (yellow-arrows).
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in synchrony with the fibroblast colonization and collagen
deposition or that fibroblast colonization and collagen dep-
osition were insufficient to prevent the changes in patch
surface area and thickness.
Similar results to the PGA patch were observed with the
knitted PCLA patch except that fibroblast colonization per
unit area was greater and more localized in the knitted
matrix than in the PGA patch. Also, collagen formation
appeared to be greatest in the KN-PCLA patch. The dimen-
sion of the WV-PCLA patch was almost unchanged during
the 8 weeks, despite the spongy matrix scaffold degradation,
fibroblast infiltration, and collagen deposition in the sponge.
In contrast, the KN-PCLA patch permitted more host fibro-
blast infiltration than did the WV-PCLA patch. This finding
is consistent with previous reports that studied woven and
knitted Dacron polyester fabric grafts.20,21
The endocardial surface was covered by endothelial cells
in all the biomaterials tested. As Scott and colleagues22
demonstrated, our findings indicate that host endocardial
endothelial cells or endothelial progenitor cells were in-
volved in endothelialization of the endocardium. The ne-
cessity of seeding endothelial cells in biomaterials remains
controversial. To avoid thrombosis, some investigators have
constructed conduits seeded with endothelial cells before
implantation.23 On the other hand, Shi and coworkers24
demonstrated that the rapidity with which the specimens are
fixed affects the identification of endothelium in explanted
synthetic aortic grafts obtained from the patients. They also
suggested that endothelialization of synthetic arterial grafts
might occur more frequently in patients than previously
recognized.
If a biodegradable scaffold is infiltrated primarily with
fibroblasts that form a fibrous structure, localized dilatation
of the patch may occur similarly to a ventricular aneurysm
formed after a transmural myocardial infarction. However,
Malm and colleagues25 reported that unseeded absorbable,
nonwoven patches made from polyhydroxybutyrate im-
planted as transannular patches into the RVOT in 13 wean-
ling sheep could be used as a scaffold for tissue regeneration
in low-pressure systems. Our histologic results demon-
strated that the patch cells and extracellular matrix in the
biodegradable scaffolds were predominantly fibroblasts and
collagen. It has been unclear whether the nonmuscular re-
generated tissue can tolerate right ventricular pressure with-
out dilatation during the long term unless a strong and
durable biodegradable material is used. Even after the
RVOT reconstruction with a transannular patch or conduit,
the implanted material may be exposed to residual stenosis
because of remaining thick trabecular muscle through the
RVOT to pulmonary artery or may be exposed to pulmo-
nary hypertension. In these cases, the biomaterial would
require more strength to prevent its dilatation because of
increased right ventricular pressure overload.
To avoid host overcolonization of the scaffold with fi-
broblasts and eventual scar formation, in vitro autologous
cell seeding may be essential in cardiac tissue engineering.
In vitro seeding of a biodegradable material with cultured
smooth muscle cells would permit formation of a muscular
tissue within the scaffold and the formation of elastin ex-
tracellular matrix in addition to collagen formation7,26 Shi-
noka and associates23 have demonstrated the benefits of in
vitro autologous cell seeding to form mature autografts from
synthetic biodegradable tubular scaffolds. We have also
found morphologic differences between the cell-seeded and
nonseeded gelatin patches.5 The elastic properties of elastin
and strength of collagen formed by the implanted smooth
muscle cells and the capacity of smooth muscle cells to
proliferate and hypertrophy in response to increased pres-
sure should prevent patch dilatation and thinning.
One limitation of this study is the small size of the
patches in the right ventricular outflow tract. Our ultimate
goal is to create a beating conduit that will provide pulsatile
perfusion to the lungs. Our preliminary study12 with seeding
a gelatin patch with fetal cardiomyocytes suggests that a
beating patch may be possible in the right ventricular out-
flow tract. However, allogeneic cells are eventually rejected,
and a better biomaterial would be required before assessing
cell-seeded grafts. Therefore this study reviewed alternative
scaffolds that can be used for cell seeding. It should be
possible to seed a biodegradable scaffold with beating car-
diomyocytes derived from mesenchymal stem cells and to
use the scaffold in vivo to induce pulsatile pulmonary
perfusion. A challenge for all biodegradable patches is to
seed the correct number and proportion of myocytes, endo-
thelial cells and fibroblasts so that the graft can develop in
vivo into a structurally strong tissue that does not dilate in
response to intraventricular pressures. With a large graft,
selective endothelial cell seeding of the endocardial surface
may be necessary before implantation to ensure complete in
vivo endothelial coverage of the graft’s endocardial surface.
In summary, the unique structure of the PCLA patch with
a spongy matrix favors in vivo cell colonization relative to
the other patches tested. Its outer poly-L-lactide fabric layer
also offers advantages relative to the other biodegradable
materials we studied.
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